Aivita Biomedical, an Irvine, Calif.- based global biotech specialized applications, raises $15m in a Series B financing.
Financing was provided by SFC Co. Ltd., a South Korean financial specialist that is recorded on the KOSDAQ Stock Exchange.
The organization will utilize the assets to propel its clinical-stage programs, expand its consumer product contributions and acquire extra staff.
Aivita Biomedical is working along with the progression of commercial and clinical-based programs using curative and regenerative pharmaceuticals. Led by Dr. Hans Keirstead, CEO, The organization uses its expertise in stem cell growth and development and coordinated high-purity separation to empower manufacturing frameworks which bolster its business line of healthy skin products and therapeutic pipeline.
Aivita has both clinical and business programs. Its lead remedial applicant is a novel patient-particular immunotherapy for the treatment of advanced tumors, at present being utilized to treat ovarian cancer. The organization has likewise propelled a consumer skincare line, ROOT OF SKIN™, which emulates the environment of developing skin. Its proprietory actives complex, SourceCode Technology™, is only made in its clinical-grade research facilities and accessible just in ROOT OF SKIN™ items.
Check Out : TOP BIOTECH STARTUPS IN EUROPE